BNP Paribas Financial Markets’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-65,943
| Closed | -$3.41M | – | 4989 |
|
|
2022
Q3 | $3.41M | Buy |
65,943
+52,256
| +382% | +$2.16M | 0.01% | 1581 |
|
|
2022
Q2 | $339K | Sell |
13,687
-70,168
| -84% | -$1.55M | ﹤0.01% | 2859 |
|
|
2022
Q1 | $2.1M | Sell |
83,855
-12,275
| -13% | -$345K | ﹤0.01% | 1771 |
|
|
2021
Q4 | $3.5M | Sell |
96,130
-7,961
| -8% | -$279K | 0.01% | 1598 |
|
|
2021
Q3 | $1.78M | Sell |
104,091
-5,627
| -5% | -$87.7K | ﹤0.01% | 1987 |
|
|
2021
Q2 | $1.47M | Sell |
109,718
-12,433
| -10% | -$306K | ﹤0.01% | 1938 |
|
|
2021
Q1 | $6.26M | Buy |
122,151
+50,353
| +70% | +$3.03M | 0.01% | 1041 |
|
|
2020
Q4 | $4.45M | Buy |
71,798
+60,185
| +518% | +$3.45M | 0.01% | 1207 |
|
|
2020
Q3 | $636K | Buy |
11,613
+7,340
| +172% | +$395K | ﹤0.01% | 2070 |
|
|
2020
Q2 | $246K | Sell |
4,273
-10,437
| -71% | -$568K | ﹤0.01% | 2408 |
|
|
2020
Q1 | $591K | Buy |
14,710
+9,920
| +207% | +$421K | ﹤0.01% | 2259 |
|
|
2019
Q4 | $189K | Sell |
4,790
-1,201
| -20% | -$21.1K | ﹤0.01% | 2983 |
|
|
2019
Q3 | $40.6K | Buy |
5,991
+3,462
| +137% | +$26K | ﹤0.01% | 3593 |
|
|
2019
Q2 | $23.5K | Sell |
2,529
-2,167
| -46% | -$25.1K | ﹤0.01% | 3841 |
|
|
2019
Q1 | $65.2K | Buy |
4,696
+4,686
| +46,860% | +$53.6K | ﹤0.01% | 3362 |
|
|
2018
Q4 | $109 | Sell |
10
-728
| -99% | -$7.68K | ﹤0.01% | 4172 |
|
|
2018
Q3 | $9.33K | Hold |
738
| – | – | ﹤0.01% | 3766 |
|
|
2018
Q2 | $9.72K | Sell |
738
-4,624
| -86% | -$55.3K | ﹤0.01% | 3793 |
|
|
2018
Q1 | $72.9K | Buy |
5,362
+184
| +4% | +$1.9K | ﹤0.01% | 3353 |
|
|
2017
Q4 | $30.8K | Buy |
5,178
+3,019
| +140% | +$20.7K | ﹤0.01% | 3870 |
|
|
2017
Q3 | $16K | Sell |
2,159
-175
| -7% | -$1.46K | ﹤0.01% | 3703 |
|
|
2017
Q2 | $21.8K | Buy |
2,334
+2,271
| +3,605% | +$16.7K | ﹤0.01% | 3609 |
|
|
2017
Q1 | $459 | Sell |
63
-1,073
| -94% | -$7.73K | ﹤0.01% | 3863 |
|
|
2016
Q4 | $8.41K | Sell |
1,136
-420
| -27% | -$3.02K | ﹤0.01% | 3526 |
|
|
2016
Q3 | $9.4K | Buy |
1,556
+715
| +85% | +$3.38K | ﹤0.01% | 3190 |
|
|
2016
Q2 | $3.78K | Buy |
+841
| New | +$3.16K | ﹤0.01% | 3368 |
|
|
2016
Q1 | – | Sell |
-5,314
| Closed | -$43K | – | 3202 |
|
|
2015
Q4 | $43K | Sell |
5,314
-1,218
| -19% | -$8.62K | ﹤0.01% | 2912 |
|
|
2015
Q3 | $39.5K | Buy |
6,532
+4,205
| +181% | +$30.4K | ﹤0.01% | 3029 |
|
|
2015
Q2 | $19.2K | Buy |
2,327
+1,676
| +257% | +$13.3K | ﹤0.01% | 3075 |
|
|
2015
Q1 | $4.92K | Buy |
+651
| New | +$5.09K | ﹤0.01% | 3170 |
|
|
2014
Q4 | – | Sell |
-1,715
| Closed | -$7.72K | – | 3426 |
|
|
2014
Q3 | $7.72K | Buy |
+1,715
| New | +$9.06K | ﹤0.01% | 3707 |
|
|
2014
Q2 | – | Sell |
-8
| Closed | -$44 | – | 3992 |
|
|
2014
Q1 | $44 | Sell |
8
-310
| -97% | -$2.15K | ﹤0.01% | 3331 |
|
|
2013
Q4 | $1.84K | Buy |
+318
| New | +$1.64K | ﹤0.01% | 3699 |
|
|
2013
Q3 | – | Sell |
-10,218
| Closed | -$144K | – | 2760 |
|
|
2013
Q2 | $144K | Buy |
+10,218
| New | +$132K | ﹤0.01% | 2449 |
|
Other funds holding CCXI
BNP Paribas Financial Markets's CCXI Position: Q4 2022 in Review
BNP Paribas Financial Markets sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 65,943 shares — an estimated $3.41M sold.
BNP Paribas Financial Markets first reported a position in CCXI in Q2 2013 and held it in 34 quarters. The position peaked at $6.26M in Q1 2021. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- BNP Paribas Financial Markets reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- BNP Paribas Financial Markets sold 65,943 ChemoCentryx, Inc. shares in Q4 2022, an estimated $3.41M.
- BNP Paribas Financial Markets first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 34 quarters.
- BNP Paribas Financial Markets's ChemoCentryx, Inc. position peaked at $6.26M in Q1 2021.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.